Bariatrics Clinical Trial - Celgene RPC01-3203

CONDITION(S): Crohn Disease - TRIAL: Celgene RPC01-3203 - This is a Phase 3, randomized, double-blind, placebo-controlled study to demonstrate the effect of oral ozanimod as maintenance therapy in subjects with moderately to severely active Crohn's Disease.A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

Drug

Drug: Ozanimod Other: Placebo

Trial Type

Interventional

Phase

Phase 3

Condition

Crohn's Disease

Keywords

Weight loss | Bariatrics